Polymorphisms of cancer stem cell marker gene CD133 are associated with susceptibility and prognosis of gastric cancer

This study was aimed to investigate the associations between single nucleotide polymorphisms of cancer stem cell marker genes, CD44 and CD133, and susceptibility and prognosis of gastric cancer. Five single nucleotide polymorphisms in CD44 and CD133 genes were genotyped in 898 gastric cancer cases a...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2017-05, Vol.13 (11), p.979-989
Main Authors: Jia, Zhi-Fang, Wu, Yan-Hua, Cao, Dong-Hui, Cao, Xue-Yuan, Jiang, Jing, Zhou, Bao-Sen
Format: Article
Language:English
Subjects:
AC133 Antigen - genetics
Aged
Alleles
Binding sites
Biomarkers
Biomarkers, Tumor
Chemotherapy
Deoxyribonucleic acid
DNA
Female
Gastric cancer
Genes
Genetic Predisposition to Disease
Genotype
Humans
Hyaluronan Receptors - genetics
Infections
Lung cancer
Male
Medical prognosis
Metastasis
Middle Aged
Neoplasm Staging
Neoplastic Stem Cells - metabolism
Odds Ratio
Polymorphism
Polymorphism, Single Nucleotide
Prognosis
Stem cells
Stomach Neoplasms - diagnosis
Stomach Neoplasms - genetics
Stomach Neoplasms - mortality
Stomach Neoplasms - therapy
Studies
Surgery
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was aimed to investigate the associations between single nucleotide polymorphisms of cancer stem cell marker genes, CD44 and CD133, and susceptibility and prognosis of gastric cancer. Five single nucleotide polymorphisms in CD44 and CD133 genes were genotyped in 898 gastric cancer cases and 992 controls. The A/C or C/C genotypes of CD133 rs2240688 were associated with decreased risk of gastric cancer comparing with the A/A genotype (odds ratio: 0.81; 95% CI: 0.67-0.97; p = 0.023). The T allele of CD133 rs3130 predicted a worse survival for gastric cancer patients receiving tumorectomy (hazard ratio: 1.28; 95% CI: 1.04-1.58; p = 0.020), independent from tumor node metastasis stage, vessel invasion and postoperational chemotherapy.  CD133 polymorphisms are promising biomarkers for genetic susceptibility and prognosis prediction of gastric cancer.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2017-0019